49 filings
8-K
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
8-K
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
CADL
Candel Therapeutics Inc
9 Apr 24
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
8:30am
8-K
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
8-K
CADL
Candel Therapeutics Inc
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
8-K
cz7919v8x7w8fg
6 Mar 24
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
8:00am
8-K
0jeqh68
13 Feb 24
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
7:45am
8-K
ef6e2xcr
12 Jan 24
Departure of Directors or Certain Officers
4:30pm
8-K
53e5clr7tph 2j0b
3 Jan 24
Other Events
8:30am
8-K
9a0ecii4qd9 lft0bj
14 Dec 23
Departure of Directors or Certain Officers
6:33pm
8-K
3rd 2gfrcint
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
cv4wb0ogtm8g4ar
28 Nov 23
Cost Associated with Exit or Disposal Activities
9:00am
8-K
c40n 7q0g0dljtqnj
21 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
w3a h90hj3
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
8-K
fvq mwr97mszlb
6 Nov 23
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
8:53am
8-K
15pbdacov3m14vq 6hl
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
ch441hh eu4t8nr44fw
18 Oct 23
Regulation FD Disclosure
11:31am
8-K
fykdn
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
8-K
zcq2onx 65
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
8-K
qk3hg6apfdqtovv
29 Jun 23
Submission of Matters to a Vote of Security Holders
8:31am